Regulatory Filing :

Taiwan Japan

Mechanism of Action :

Maxacalcitol inhibits the PTH secretion effect on parathyroid cells in normal cattle and in parathyroid cells in people with chronic renal atrophy (in vitro), and this inhibitory effect is similar to that of calcitriol. 

A model study of renal failure in animals (rats with five-sixth kidney removed and dogs with ligation of renal artery) showed that maxacalcitol inhibits PTH secretion at a dose that does not increase serum calcium concentration.

Indication :

Maxacalcitol is indicated for secondary hyperparathyroidism of the patients receiving maintenance dialysis.

Disclaimer
 

Please be reminded that some products listed above are still patented and can only be made available for R & D use as permitted under 35 USC ¶ 271 (e) (1); Article 69, Paragraph 1 of the Patent Act of Japan; Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004; or Article 69 (5) of the Patent Law of People’s Republic of China; or Article 60 of the Patent Act of Republic of China. We will not make, sell, offer for commercial sale or export the products listed above in/into regions or countries in which substance patents are still existing and we will not be responsible if the use of any of the above products infringes on any patent in your country.

Close